Peer-influenced content. Sources you trust. No registration required. This is HCN.

Psychiatrist.comTopiramate Monotherapy for Civilian Posttraumatic Stress Disorder: A Controlled Pilot Study

Topiramate Shows Promise in Reducing PTSD Symptoms

A recent study investigated the efficacy and safety of topiramate monotherapy in treating civilian posttraumatic stress disorder (PTSD). The study was a double-blind, placebo-controlled trial involving outpatients aged between 18 and 64 years.

Study Design

  • The study involved outpatients aged between 18 and 64 years with DSM-IV non-combat-related PTSD.
  • Participants were required to have Clinician-Administered PTSD Scale (CAPS) scores of 50 or higher.
  • Topiramate was started at 25 mg/day and titrated by 25-50 mg/week to 400 mg/day or maximum tolerated dose.
  • Data were collected between April 26, 2002, and February 4, 2004.

Key Findings

  • The intent-to-treat (ITT) population comprised 38 patients with mean baseline total CAPS scores of 88.3 (topiramate, N = 19) and 91.1 (placebo, N = 19).
  • Although a decrease in total CAPS score was noted (topiramate, -52.7; placebo, -42.0), this difference was not statistically significant (p = .232).
  • Topiramate-treated patients exhibited significant reductions in reexperiencing symptoms (CAPS cluster B: topiramate, 74.9%; placebo, 50.2%; p = .038) and Treatment Outcome PTSD scale (topiramate, 68.0%; placebo, 41.6%; p = .025).

According to the National Institute of Mental Health, about 3.6% of US adults had PTSD in the past year.

More on Topiramate

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form